BRIEF—Mitsubishi Tanabe secures additional indication for Novastan in China

Japan’s Mitsubishi Tanabe has won approval from the China Food and Drug Administration for a new indication for Novastan (argatroban).

The company may now market the drug for “improvement of neurological abnormalities (motor paralysis) and activities of daily living associated with acute cerebral thrombosis.”

Mitsubishi Tanabe won its first approval in Japan for the therapy in 1990, and in China in 1999.